Dual biologic therapy with Omalizumab and Dupilumab for refractory atopic disease

Australas J Dermatol. 2022 Feb;63(1):110-111. doi: 10.1111/ajd.13743. Epub 2021 Nov 10.

Authors

Alexis Arasu¹, Niyati Sharma², Anousha Yazdabadi^{3

4}, Michael Sladden⁵

Affiliations

¹ Alfred Health, Melbourne, Victoria, Australia.
² Department of Dermatology, Monash Health, Clayton, Victoria, Australia.
³ Department of Dermatology, Eastern Health, Box Hill, Victoria, Australia.
⁴ Department of Medical Education, University of Melbourne, Melbourne, Victoria, Australia.
⁵ Department of Medicine, University of Tasmania, Launceston, Tasmania, Australia.

PMID: 34755893
DOI: 10.1111/ajd.13743

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Biological Therapy / methods*
Dermatitis, Atopic / drug therapy*
Humans
Omalizumab / therapeutic use*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Omalizumab
dupilumab